| Literature DB >> 31285827 |
Hirotaka Nishijima1,2,3,4, Kazuyuki Kominami2, Kazuo Kondo3, Masatoshi Akino1,2, Masayuki Sakurai4.
Abstract
BACKGROUND: Ventilatory anaerobic threshold (VAT) is a useful submaximal measure of exercise tolerance; however, it must be visually determined. We developed a new mathematical method to objectively determine VAT.Entities:
Keywords: Cardiac rehabilitation; Exponential fitting; V-slope
Year: 2019 PMID: 31285827 PMCID: PMC6592010 DOI: 10.1186/s13102-019-0122-z
Source DB: PubMed Journal: BMC Sports Sci Med Rehabil ISSN: 2052-1847
Demographic and clinical characteristics (populations A and B)
| Population A healthy ( | Population A with CV risks ( | Population A cardiac ( | Population B cardiac ( | |
|---|---|---|---|---|
| Age, y | 37 ± 20* | 59 ± 11 | 67 ± 9 | 63 ± 10 |
| Sex (male/female) | 48/19 | 20/0 | 26/15 | 141/22 |
| Body weight, kg | 62 ± 11* | 72 ± 7 | 59 ± 9 | 66.1 ± 10.9 |
| Body mass index, kg/m2 | 22.1 ± 3.0* | 25.8 ± 2.8 | 23.3 ± 3.1 | 24.7 ± 3.2 |
| Heart disease etiology: ischemic (%) | NA | NA | 76 | 84 |
| Weber class: A/B/C/D† | NA | NA | ||
| Using VO2peak (n) | 7/12/20/2 | NA | ||
| Using VAT (n) | 1/16/18/6 | 11/40/66/29 | ||
| Medications (n) | NA | |||
| ACE or ARB | 9 | 16 | 91 | |
| Diuretic | 2 | 7 | 51 | |
| Beta-blocker | 0 | 17 | 72 | |
| Inotropics | 0 | 0 | 4 | |
| Ca channel blocker | 17 | 7 | 35 | |
| Anti-lipidemic | 3 | 16 | 85 | |
| Anti-diabetic | 2 | 4 | 42 |
*p-Value was significant at least at < 0.05 by 1-way analysis of variance
†Weber-Janicki functional classification: Using VO2peak, based on VO2peak; Using VAT, based on the ventilatory anaerobic threshold
CV cardiovascular, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, Ca calcium
Fig. 1(left) Diagram showing the method of determination of expVAT (VCO2), and (right) expVAT (VE). expVAT (VCO2), VAT derived from exponential fitting of the V-slope (VCO2 vs. VO2). expVAT (VE), VAT derived from exponential fitting of the relation VO2 vs. VE (p) (30 y/o healthy female weighing 57 kg).
Cardiopulmonary exercise and derived variables of population A (maximal exercise)
| Healthy subjects | Patients with CV risk factors | Cardiac subjects | |
|---|---|---|---|
| Peak work rate, W | 170 ± 65* | 121 ± 36 | 71 ± 28 |
| Ramp duration, s | 550 ± 139 | 572 ± 132 | 494 ± 148 |
| Peak Borg scale | 16.7 ± 1.3* | 16.8 ± 1.4 | 15.4 ± 1.6 |
| Peak HR, beats/min | 164 ± 23* | 134 ± 27 | 117 ± 19 |
| %Predicted peak HR | 90 ± 9.5* | 83 ± 13 | 77 ± 12 |
| VO2peak, mL/min | 2031 ± 728* | 1581 ± 413 | 973 ± 323 |
| VO2peak, mL/kg/min | 32.2 ± 9.2* | 22.0 ± 6.0 | 16.0 ± 4.0 |
| Peak R | 1.18 ± 0.09 | 1.15 ± 0.09 | 1.14 ± 0.10 |
| vVAT, mL/min | 1042 ± 310* | 916 ± 237 | 629 ± 169 |
| vVAT, mL/min/kg | 16.7 ± 4.1* | 12.6 ± 3.2 | 10.4 ± 1.9 |
| expVAT (VCO2), mL/min | 1085 ± 353* | 874 ± 199 | 589 ± 168 |
| expVAT (VCO2), mL/min/kg | 17.2 ± 4.2* | 12.1 ± 2.7 | 9.7 ± 2.0 |
| Exponential coefficient | 1.0012 ± 0.0003* | 1.0013 ± 0.0002 | 1.0020 ± 0.0006 |
| expVAT (VE), mL/min | 1053 ± 295* | 884 ± 203 | 634 ± 176 |
| expVAT (VE), mL/min/kg | 16.7 ± 3.4* | 12.2 ± 2.8 | 10.4 ± 2.3 |
| Exponential coefficient | 1.0010 ± 0.0003* | 1.0011 ± 0.0002 | 1.0017 ± 0.0006 |
| OUES (VCO2), mL/min | 2036 ± 599* | 1725 ± 345 | 1197 ± 326 |
| OUES (VE), mL/min | 2386 ± 679* | 1988 ± 451 | 1413 ± 404 |
*p-Value was significant at least at < 0.05 by 1-way analysis of variance.
HR heart rate, VO oxygen uptake, R respiratory exchange rate, vVAT visual ventilatory anaerobic threshold: expVAT (VCO2), exponential VAT based on VO2 vs. VCO2; expVAT (VE), exponential VAT based on VO2 vs. VE; OUES (VCO2), oxygen uptake efficiency slope based on logVCO2 vs. VO2; OUES (VE), oxygen uptake efficiency slope based on logVE vs. VO2
Correlation matrix of exercise tolerance variables (population A)
| VO2peak | vVAT | expVAT | expVAT | OUES | OUES | |
|---|---|---|---|---|---|---|
| VO2peak | 0.882 | 0.971 | 0.932 | 0.968 | 0.935 | |
| vVAT | 0.882 | 0.924 | 0.903 | 0.914 | 0.897 | |
| expVAT (VCO2) | 0.971 | 0.924 | 0.970 | 0.987 | 0.970 | |
| expVAT (VE) | 0.932 | 0.903 | 0.970 | 0.970 | 0.998 | |
| OUES (VCO2) | 0.968 | 0.914 | 0.987 | 0.970 | 0.971 | |
| OUES (VE) | 0.935 | 0.897 | 0.970 | 0.998 | 0.971 |
All r values are significant at p < 0.001. Abbreviations are the same as in Table 2
Fig. 2Relation between (top) VO2peak vs. expVAT (VCO2), (middle) vVAT vs. expVAT (VCO2), and (bottom) VO2peak vs. vVAT. Abbreviations are the same as in Fig. 1.
Fig. 3Bland and Altman plot between vVAT and expVAT. (top) expVAT (VCO2) and (bottom) expVAT (VE).
Cardiopulmonary exercise and derived variables of population B (submaximal exercise: before/after cardiac rehabilitation)
| Before | After | ||
|---|---|---|---|
| Body weight, kg | 66.1 ± 10.9 | 66.7 ± 10.9 | 0.008 |
| Highest work rate, Wa | 66 ± 20 | 82 ± 24 | < 0.001 |
| Ramp exercise duration, s | 360 ± 107 | 438 ± 121 | < 0.001 |
| Highest Borg scalea, /20 | 14.1 ± 1.7 | 14.7 ± 1.9 | < 0.001 |
| Highest HRa, beats/min | 109 ± 18 | 116 ± 18 | < 0.001 |
| Highest VO2a, mL/min | 971 ± 285 | 1146 ± 341 | < 0.001 |
| Highest VO2a, mL/min/kg | 14.6 ± 3.4 | 17.0 ± 4.0 | < 0.001 |
| Highest Ra | 1.06 ± 0.10 | 1.09 ± 0.11 | < 0.001 |
| vVAT, mL/min | 673 ± 191 | 734 ± 226 | < 0.001 |
| vVAT, mL/min/kg | 10.1 ± 2.4 | 10.8 ± 2.8 | < 0.001 |
| expVAT (VCO2), mL/min | 641 ± 185 | 685 ± 201 | < 0.001 |
| expVAT (VCO2), mL/min/kg | 9.6 ± 2.3 | 10.2 ± 2.4 | < 0.001 |
| Exponential coefficient, “ | 1.0018 ± 0.0004 | 1.0017 ± 0.0004 | 0.001 |
| expVAT (VE), mL/min | 696 ± 182 | 727 ± 209 | 0.008 |
| expVAT (VE), mL/min/kg | 10.6 ± 2.7 | 10.9 ± 2.7 | 0.074 |
| Exponential coefficient, “ | 1.0015 ± 0.0004 | 1.0014 ± 0.0004 | 0.011 |
| OUES (VCO2), mL/min | 1306 ± 327 | 1385 ± 355 | < 0.001 |
| OUES (VE), mL/min | 1513 ± 398 | 1610 ± 467 | < 0.001 |
aAs the exercise protocol was submaximal, the last value was simply designated as the highest value (see the “CPX” subsection in Methods). Abbreviations are the same as in Table 2